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Abstract
As members of the Pan American Health Organization (PAHO) and World Health Organiza-
tion (WHO) guidelines development group on chemotherapy strategies for the control of
Taenia solium taeniasis, we are very disappointed at the systematic review by Haby and col-
leagues. With respect to the analysis of efficacy, the authors did not account for differences
in the methods used to ascertain the outcome in the studies analyzed. There are also major
concerns regarding the safety analyses. Few of the included studies used carefully
designed active surveillance protocols to detect epileptic seizures and/or chronic progres-
sive headaches. These neurologic side effects, due the inadvertent killing of viable brain
cysts, have been noted after mass therapy with praziquantel and albendazole. We whole-
heartedly agree with the authors’ statement in their discussion that control programs apply-
ing chemotherapy using mass drug administration “need to be informed by evidence of the
best drug and dose in terms of efficacy and side-effects.” Unfortunately, the flawed analysis
that was published is contrary to that goal.
As members of the Pan American Health Organization (PAHO) and World Health Organiza-
tion (WHO) guidelines development group on chemotherapy strategies for the control of Tae-
nia solium taeniasis, we are very disappointed at the systematic review by Haby and colleagues.
[1] In prior deliberations and discussions with the authors, we highlighted major methodolo-
gic flaws in the current analysis. However, these flaws were not addressed in this meta-analysis,
and the manuscript was published without us seeing it beforehand. Unfortunately, the pub-
lished version includes substantial biases that, if considered properly, would have likely contra-
dicted the current conclusions. In particular, we disagree with the authors’ conclusions in
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support of the efficacy and safety of albendazole (ABZ) and praziquantel in mass drug
administration.
With respect to the analysis of efficacy, the authors did not account for differences in the
methods used to ascertain the outcome in the studies analyzed. Stool-based diagnosis of taeni-
asis can be accomplished through visualization of eggs using microscopy, detection of
coproantigens (coAg) via immunoassays, and amplification of DNA using polymerase chain
reaction. A critical oversight in this meta-analysis was disregarding the disparity in the sensi-
tivity and specificity of these methods. All of the studies involving ABZ included in the meta-
analysis relied solely on microscopy to assess treatment efficacy, [2, 3] a method that is notori-
ously insensitive and cannot distinguish T. solium from T. saginata. Microscopy is also subject
to inaccurate interpretation of the temporary cessation of egg shedding that may occur when
terminal proglottids are killed but the scolex remains viable. Both limitations would result in
misclassification of persistent infections as cured and would therefore be expected to overesti-
mate the efficacy of ABZ. In contrast, coAg detection was disproportionately used in studies of
niclosamide and praziquantel. coAg detection is much more sensitive than microscopy and
remains positive during temporary cessation of egg shedding. [4] In some of the included stud-
ies, the outcome was assessed through coAg detection of serial stool samples, further increas-
ing the sensitivity. These latter approaches all limit the likelihood of misclassification of
persistent infections as cured. Direct comparison of studies that measure treatment efficacy
with microscopy versus coAg detection, as was done in this meta-analysis, will invariably bias
in favor of studies that use the method with lower sensitivity. The fact that most of these tests
also have different specificity values cannot be discounted as it will invariably introduce vari-
ous levels of biases across studies. Moreover, the authors pooled the results (see their Fig 3 and
Fig 4) from all studies, which used different drugs, doses, treatment regimens, and diagnostic
tests, increasing the risk for flawed conclusions.
There are also major concerns regarding the safety analyses. Few of the included studies
used carefully designed active surveillance protocols to detect epileptic seizures and/or chronic
progressive headaches, the main neurologic side effects that would be anticipated in the inad-
vertent killing of viable brain cysts. Epileptic seizures are highly stigmatizing in most countries
where cysticercosis is endemic, which would lead to underreporting of these symptoms, espe-
cially in studies not specifically designed to measure these effects. In addition, none of the
studies followed participants during the period in which neurologic side effects would be antic-
ipated to occur (days 3 to 5 after treatment). Thus, we do not feel that there is any good data to
support safety of ABZ or praziquantel in areas that are endemic for T. solium. In fact, results
from a prospective study on neurologic side effects after mass drug administration of prazi-
quantel for schistosomiasis have identified neurologic side effects likely due to occult cysticer-
cosis. [5, 6] A detailed management plan for neurologic side effects from occult
neurocysticercosis should be at the core of every mass drug administration program with pra-
ziquantel and/or ABZ in areas endemic for T. solium.
We wholeheartedly agree with the authors’ statement in their discussion that control pro-
grams applying chemotherapy using mass drug administration “need to be informed by evi-
dence of the best drug and dose in terms of efficacy and side-effects.” Unfortunately, the
flawed analysis that was published is contrary to that goal. Rather than promoting questionable
conclusions based on weak evidence and inappropriate analyses, we believe that all stakehold-
ers would be better served by pursuing more robust evidence to inform safe and effective
interventions.
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